SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-22-009882
Filing Date
2022-05-13
Accepted
2022-05-13 16:56:31
Documents
12
Period of Report
2022-05-11
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K kzr-20220511.htm   iXBRL 8-K 49597
  Complete submission text file 0000950170-22-009882.txt   166844

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kzr-20220511_pre.xml EX-101.PRE 9953
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kzr-20220511_lab.xml EX-101.LAB 13438
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kzr-20220511.xsd EX-101.SCH 2519
6 EXTRACTED XBRL INSTANCE DOCUMENT kzr-20220511_htm.xml XML 4715
Mailing Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 650-822-5600
Kezar Life Sciences, Inc. (Filer) CIK: 0001645666 (see all company filings)

IRS No.: 473366145 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38542 | Film No.: 22923698
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences